Politics
Drug Affordability Act Criticized
The Medication Affordability and Patent Integrity Act is facing criticism for potentially hindering drug development without addressing prescription drug prices. Critics argue it imposes new regulatory burdens on biotech companies.
Coverage timeline — 1 article
The Hill
The Medication Affordability and Patent Integrity Act would create new regulatory burdens on biotech companies, making it harder and taking longer to develop new treatments, while doing nothing to lower prescription drug prices.
2026-06-16 13:30 UTC